Pharmaceutical company Sunshine Biopharma’s HMEC study has indicated the non-toxicity of anticancer compound Adva-27a to healthy tissue at high concentrations.
According to the data, concentrations of up to 24 micromolar of Adva-27a did not measurably inhibit the normal growth process of these cells.
Sunshine Biopharma CEO Dr Steve Slilaty said the data indicates the non-toxicity of Adva-27a to healthy tissue.
"This further confirms that Adva-27a will have great utility for cancer therapy in humans, particularly in view of the fact that twenty-four micromolar is over three times the actual concentration estimated to ultimately be used in patient therapy," Slilaty said.
The company completed several new IND-Enabling studies, including one in which the cytotoxic activity of Adva-27a was measured in the HMEC cell line.
HMEC are non-cancerous human mammary epithelial cells isolated from reduction mammoplasty tissu,e and HMEC is the standard cell line used for ascertain the molecular and biochemical basis for in-vitro toxicity of drug candidates.
Adva-27a has previously established efficacy at killing different types of multidrug resistant cancer cell lines, such as MES-SA/Dx5, a Uterine Sarcoma cell line, MCF-7/MDR, a breast cancer cell line and H69AR, a small-cell lung cancer cell line.
